Program
Actinium Ac 225 GPC3-targeted Peptide RYZ801
Its studies are mostly in Carcinoma, Hepatocellular, led by Bristol-Myers Squibb.
Furthest: phase 2, since Nov 5, 20241 company-led study, 1 open or runningNext primary completion: Jun 2030 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 11 open or running | phase 2since Nov 5, 2024 | Nov 5, 2024 | Jun 2030phase 2 · NCT06726161 |
- Named in Bristol-Myers Squibb’s own pipeline as
RYZ801
, phase 1, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 5, 2024First study: phase 2 study in Carcinoma, HepatocellularFirst studyNCT06726161 · 590 planned · United States
Ahead
- Jun 2030Primary completion: phase 2 study in Carcinoma, HepatocellularNCT06726161
TargetBeta
“A radioconjugate composed of a glypican-3 (GPC3; GPC-3)-binding peptide conjugated to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity against GPC3-expressing tumor cells. Upon administration of actinium Ac 225 GPC3-targeted peptide RYZ801, the GPC3-binding …”NCIt, read by Claude
Other programs on GPC3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033rule | BeOne Medicines | phase 3 | 3 |
| codrituzumab | Hoffmann-La Roche | phase 2 | 3 |
| GPC3-targeted Plasmid DNA Vaccine NWRD06rule | Newish Biotech (Wuxi) | phase 2 | 2 |
| Anti-GPC3 T Cell-engaging Antibody AZD9793 | AstraZeneca | phase 2 | 1 |
| Anti-GPC3 Antibody-drug Conjugate ZW251rule | Zymeworks | phase 1 | 1 |
| Anti-GPC3 Antibody-drug Conjugate ABBV-324 | AbbVie | phase 1 | 1 |
| Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926rule | Bayer | phase 1 | 1 |
| ACE723rule | acepodia-biotech-inc | phase 1 | 1 |
| TQB6426rule | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06726161Carcinoma, Hepatocellular · United States | 2 | Recruiting | Jun 2030 | 590 |
How it is read
Names in the registry
- “RYZ801”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.